Nf Κb (Nuclear Factor Kappa B) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NF-κB[@mattson2001] (nuclear factor kappa-light-chain-enhancer of activated B cells) is a family of transcription factors that plays central roles in inflammation, immune responses, cell survival, and synaptic plasticity. In the central nervous system, NF-κB[@mattson2001] is activated in neurons, astrocytes, and microglia, where it serves as a critical mediator linking neuroinflammation to neuronal death in Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease (Mattson & Camandola, 2001; Singh & Singh, 2020). [@hayden2008]
NF-κB occupies a paradoxical position in neurodegeneration: in neurons, it is generally neuroprotective, promoting survival through anti-apoptotic gene expression, while in microglia and astrocytes, it drives pro-inflammatory cascades that exacerbate neuronal damage (Jha et al., 2024). This dual nature makes NF-κB both a compelling and a challenging therapeutic target.
The NF-κB[@mattson2001] family consists of five related proteins that form homo- and heterodimers with distinct DNA-binding specificities and transcriptional targets (Hayden & Ghosh, 2008): [@ju2022]
| Subunit | Gene | Precursor | Key Features | [@jha2024]
|---------|------|-----------|--------------| [@lian2024]
| p65 (RelA) | RELA | — | Contains transactivation domain; most abundant subunit in CNS | [@snow2021]
| RelB | RELB | — | Induces distinct transcriptional programs via non-canonical pathway | [@singh2020]
| c-Rel | REL | — | Important for lymphocyte function; expressed in neurons | [@thakur2023]
| p50 (NF-κB[@mattson2001]1) | NFKB1 | p105 | Processed from p105 precursor; lacks transactivation domain | [@shi2025]
| p52 (NF-κB[@mattson2001]2) | NFKB2 | p100 | Processed from p100; active in non-canonical signaling | [@bido2024]
The p65/p50 heterodimer is the most common transcriptionally active form in the brain and is the primary mediator of inflammatory gene expression in microglia and astrocytes (Karin & Ben-Neriah, 2000). [@gupta2023]
The canonical NF-κB[@mattson2001] pathway is the primary signaling route in neuroinflammation[@karin2000] (Hayden & Ghosh, 2008): [@sun2011]
This pathway mediates rapid, transient responses and is the primary driver of microglial inflammatory activation. [@astrocytes]
The non-canonical pathway involves NF-κB[@mattson2001]-inducing kinase (NIK) and IKKα-mediated processing of p100 to p52, which pairs with RelB. This pathway produces slower, sustained responses and is particularly important for lymph node development and adaptive immune regulation. In the CNS, the non-canonical pathway contributes to astrocyte activation and synaptic maintenance (Sun, 2011). [@microgliacelltypesmicroglia]
In neurons, NF-κB[@mattson2001] is constitutively active at low levels and serves primarily protective functions (Mattson, 2005): [@trem]
Synaptic plasticity and memory: [@tau]
Neuronal survival: [@nfkb]
In contrast to its protective neuronal role, glial NF-κB [@mattson2001] activation is a central driver of neurotoxic neuroinflammation [@karin2000]: [@nfkba]
Microglial activation (Snow & Albensi, 2021): [@nfkbb]
Astrocyte activation (Lian et al., 2024): [@nfkbc]
NF-κB[@mattson2001] is chronically hyperactivated in Alzheimer's disease brain tissue, particularly in vulnerable regions including the hippocampus and [entorhinal cortex (Singh et al., 2022):
NF-κB[@mattson2001] participates in a destructive feed-forward loop with amyloid-beta (Ju Hwang et al., 2022):
NF-κB[@mattson2001] also links to tau] hyperphosphorylation]:
NF-κB[@mattson2001] plays a significant role in dopaminergic neurodDegeneration in Parkinson's disease (Singh & Singh, 2020):
ALS: Spinal cords of ALS patients show increased NF-κB[@mattson2001] activation in astrocytes associated with degenerating motor neurons. Mutant [SOD1/proteins/sod1-mediated NF-κB[@mattson2001] activation in glia contributes to non-cell-autonomous motor neuron toxicity (Mattson & Camandola, 2001).
Huntington's disease: In contrast to its deleterious role in AD and PD glia, neuronal NF-κB[@mattson2001] appears protective in HD. Mice lacking the p50 subunit (NF-κB[@mattson2001]1 knockout) exhibit increased striatal neuron damage and enhanced motor dysfunction after mitochondrial toxin exposure, indicating that NF-κB[@mattson2001] activation serves a neuroprotective function in medium spiny neurons (Mattson & Camandola, 2001).
The opposing functions of NF-κB[@mattson2001] in neurons (protective) versus glia (inflammatory) make therapeutic targeting extremely challenging (Jha et al., 2024):
Direct NF-κB[@mattson2001] inhibitors (Thakur et al., 2023):
Natural product modulators:
Indirect approaches:
NF-κB[@mattson2001] serves as a signaling hub integrating multiple neurodegeneration-relevant pathways:
Recent research has identified NFκB1 (p50/p105) as a potential common biomarker linking Alzheimer's disease and Parkinson's disease disease pathology (Shi et al., 2025):
| Method | Application | Resolution |
|---|---|---|
| Immunohistochemistry | Nuclear p65 localization in tissue sections | Cellular |
| EMSA (Electrophoretic Mobility Shift Assay) | DNA-binding activity quantification | Molecular |
| Western blot | Protein levels, phosphorylation status | Molecular |
| NF-κB[@mattson2001] reporter assays | Transcriptional activity in live cells | Cellular |
| ChIP-seq | Genome-wide NF-κB[@mattson2001] binding site mapping | Genomic |
| qPCR of target genes | Downstream pathway activation | Molecular |
| Single-cell RNA-seq | Cell-type-specific NF-κB[@mattson2001] target expression | Single-cell |
The study of Nf Κb (Nuclear Factor Kappa B) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
DOI:10.1172/JCI11916
DOI:10.1016/j.cell.2008.01.020
DOI:10.1146/annurev.immunol.18.1.621
DOI:10.1385/MN:31:1-3:175
DOI:10.1002/(SICI
DOI:10.1016/j.nbd.2022.105642
7. [Ju Hwang C, et al., The pivotal role of NF-kB in the pathogenesis and therapeutics of Alzheimer's Disease. Int J Mol Sci. 2022;23(16):8972. PubMed (2022)
8. Jha NK, et al, NF-κB[1] in Alzheimer's Disease: friend or foe? Opposite functions in neurons and glial cells (2024)
DOI:10.1038/s41598-024-65248-1
DOI:10.3233/JAD-210111
PMID:31823227
DOI:10.3390/biomedicines11092587
13. Shi Y, et al, NFκB1: a common biomarker linking Alzheimer's and Parkinson's Disease pathology (2025)
DOI:10.1186/s40035-024-00401-4
15. Gupta SC, et al, NF-κB[1] in Alzheimer's Disease: role in pathogenesis and therapeutic potential (2023)
DOI:10.1038/cdd.2011.71
17. Unknown, - Astrocytes (n.d.)
18. Unknown, - Microglia/cell-types/microglia (n.d.)
19. Unknown, - [TREM2 — [Triggering Receptor Expressed on Myeloid Cells 2] (n.d.)
20. Unknown, - tau protein]## External Links (n.d.)
21. -, NF-kB — NCBI Gene (n.d.)
22. -, NF-kB Signaling Pathway — KEGG (n.d.)
23. -, NF-kB — UniProt (NFKB1) (n.d.)
24. -, NF-kB — GeneCards (n.d.)